Abstract
Protein:protein interactions are becoming increasingly significant as potential drug targets; however, the rational identification of small molecule inhibitors of such interactions remains a challenge. Pharmacophore modelling is a popular tool for virtual screening of compound libraries, and has previously been successfully applied to the discovery of enzymatic inhibitors. However, the application of pharmacophore modelling in the field of protein:protein interaction inhibitors has historically been considered more of a challenge and remains limited. In this review, we explore the interaction mimicry by known inhibitors that originate from in vitro screening, demonstrating the validity of pharmacophore mapping in the generation of queries for virtual screening. We discuss the pharmacophore mapping methods that have been successfully employed in the discovery of first-in-class inhibitors. These successful cases demonstrate the usefulness of a “tool kit” of diverse strategies for application across a range of situations depending on the available structural information.
Keywords: Drug discovery, Pharmacophore modelling, Protein:protein interaction (PPI), Small molecule protein:protein interaction inhibitor (SMPPII), Virtual screening.
Current Topics in Medicinal Chemistry
Title:Protein Interface Pharmacophore Mapping Tools for Small Molecule Protein: Protein Interaction Inhibitor Discovery
Volume: 13 Issue: 9
Author(s): Arnout Voet, Eleanor F. Banwell, Kamlesh K. Sahu, Jonathan G. Heddle and Kam Y. J. Zhang
Affiliation:
Keywords: Drug discovery, Pharmacophore modelling, Protein:protein interaction (PPI), Small molecule protein:protein interaction inhibitor (SMPPII), Virtual screening.
Abstract: Protein:protein interactions are becoming increasingly significant as potential drug targets; however, the rational identification of small molecule inhibitors of such interactions remains a challenge. Pharmacophore modelling is a popular tool for virtual screening of compound libraries, and has previously been successfully applied to the discovery of enzymatic inhibitors. However, the application of pharmacophore modelling in the field of protein:protein interaction inhibitors has historically been considered more of a challenge and remains limited. In this review, we explore the interaction mimicry by known inhibitors that originate from in vitro screening, demonstrating the validity of pharmacophore mapping in the generation of queries for virtual screening. We discuss the pharmacophore mapping methods that have been successfully employed in the discovery of first-in-class inhibitors. These successful cases demonstrate the usefulness of a “tool kit” of diverse strategies for application across a range of situations depending on the available structural information.
Export Options
About this article
Cite this article as:
Voet Arnout, Banwell Eleanor F., Sahu Kamlesh K., Heddle Jonathan G. and Zhang Kam Y. J., Protein Interface Pharmacophore Mapping Tools for Small Molecule Protein: Protein Interaction Inhibitor Discovery, Current Topics in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/1568026611313090003
DOI https://dx.doi.org/10.2174/1568026611313090003 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Current Cancer Therapy Reviews Editorial [Hot Topic: Targeted Cancer Therapies: Current Status and Future Directions (Guest Editors: Ioannis Starakis)]
Current Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Is HIV Involved in the Pathogenesis of Non-Infectious Pulmonary Complications in Infected Patients?
Current HIV Research miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Current Cancer Drug Targets Editorial [Hot Topic: Akt Pathway in Oncogenesis and as a Target for Anti-Cancer Therapy (Guest Editor: Jin Q. Cheng) ]
Current Cancer Drug Targets Using Cytochalasins to Improve Current Chemotherapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets On the Physiological Role of Cytosolic 5’-nucleotidase II (cN-II): Pathological and Therapeutical Implications.
Current Medicinal Chemistry Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication
Endocrine, Metabolic & Immune Disorders - Drug Targets Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Epstein-Barr Encephalitis in a Child with Congenital Human Immunodeficiency Virus Infection: A Case Report Calling for No Forgetfulness
Current HIV Research Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries
Current Protein & Peptide Science <i>Rhizoma Coptidis</i> for Alzheimer’s Disease and Vascular Dementia: A Literature Review
Current Vascular Pharmacology